Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHRANE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Induction and maintenance of general anesthesia
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Primarily hepatic via cytochrome P450 (CYP2E1); minor metabolism to fluoride ions.
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
Approximately 30-40%, primarily to albumin.
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
Vd: 1.2-2.0 L/kg, indicating extensive distribution into tissues, especially fat.
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
By inhalation: 100% as delivered; not administered orally.
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
No dose adjustment required for GFR >10 m L/min; use with caution in severe renal impairment (GFR <10 m L/min) due to potential accumulation of inorganic fluoride metabolites.
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
No specific Child-Pugh based adjustment; use with caution in severe hepatic impairment as metabolism may be decreased.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
Induction: 2-5% inspired concentration; Maintenance: 1-3% inspired concentration, adjusted to age and response.
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
Lower inspired concentrations (0.5-2%) recommended due to increased sensitivity and reduced clearance; titrate to effect.
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
None
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
May cause dose-dependent cardiovascular depression,Risk of malignant hyperthermia,Potential for nephrotoxicity due to fluoride release,Hepatotoxicity risk, especially with repeated use,Neurologic effects including seizure activity at high doses
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected susceptibility to malignant hyperthermia,Severe hepatic impairment,Uncontrolled epilepsy
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
No specific food interactions. Patient must follow preoperative fasting guidelines (nil per os, NPO) as directed by anesthesiologist to reduce risk of aspiration.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal hypoxia from maternal hypotension.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Excreted in breast milk in low amounts; M/P ratio not established. Consider benefits of breastfeeding vs. risk of infant exposure. Minimal systemic absorption in infant expected.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
No specific dose adjustments required for pregnancy; however, MAC decreases by approximately 30% during pregnancy due to hormonal changes and increased progesterone. Monitor depth of anesthesia closely.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
ETHRANE (enflurane) is a potent inhalation anesthetic. Its use is limited due to risk of seizures at high doses and potential for nephrotoxicity from fluoride ion release. Avoid in patients with history of seizures or renal impairment. Rapid induction and recovery; use with caution in hypotensive patients due to myocardial depression. Malignant hyperthermia trigger.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
You will receive this anesthesia medication only in a hospital setting under expert supervision.,Possible side effects include nausea, vomiting, shivering, and confusion after waking up.,Tell your doctor if you have a history of seizures, kidney problems, or muscle disorders.,Avoid driving or operating machinery for at least 24 hours after anesthesia.,Do not eat or drink for the time specified by your healthcare team before surgery.
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
No interactions on record
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHRANE vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
ETHRANE is a General Anesthetic that works by Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHRANE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHRANE is: 1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHRANE and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHRANE is classified as Category C. FDA Category B. No evidence of teratogenicity in animal studies; human data limited. Use only if clearly needed during pregnancy, especially first trimester due to potential fetal . ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.